Protection of Mice Against Dengue 2 Virus Encephalitis by Immunization with the Dengue 2 Virus Non-structural Glycoprotein NS1
|
|
- Ronald Bruce
- 5 years ago
- Views:
Transcription
1 J. gen. Viral. (1987), 68, Printed in Great Britain Key words: dengue virus/non-structural protein/vaccine 853 Protection of Mice Against Dengue 2 Virus Encephalitis by Immunization with the Dengue 2 Virus Non-structural Glycoprotein NS1 By JACOB J. SCHLESINGER,* MICHAEL W. BRANDRISS AND EDWARD E. WALSH Department of Medicine, the Rochester General Hospital and the University of Rochester School oj Medicine and Dentistry, Rochester, New York 14621, U.S.A. (Accepted 20 November 1986) SUMMARY Immunization of mice with the dengue 2 virus (DEN 2)-specified non-structural protein NS1 provided significant protection against intracerebral challenge with the virus in the absence of detectable neutralizing or other anti-virion antibody. NS1, purified from lysates of infected Vero cells by immunoaffinity chromatography, expressed an antigenic site(s) common to each of the four DEN serotypes, and hyperimmunization of rabbits with NS1 stimulated production of complement-fixing (CF) antibody with broad DEN serotype specificity. However, cross-protection was not observed: mice immunized with DEN 2 NS1 developed little or no heterologous CF antibody and were not protected against challenge with neurovirulent DEN 1. Induction of a protective immune response by NS1 suggests that it be considered for incorporation into possible synthetic or recombinant DNA DEN vaccines. Among the mosquito-borne flaviviruses of medical importance, the dengue viruses (DEN) are notable for their global distribution and the frequency of large-scale epidemics caused by them (Halstead, 1980). Attempts to produce a satisfactory DEN vaccine by conventional methods have met with limited success. Attenuated DEN vaccines have been prepared by intracerebral passage in mice (Sabin & Schlesinger, 1945: Schlesinger et al., 1956) but the undesirability of brain tissue in human vaccine preparations has restricted their use. More recently, tissue culture-derived attenuated DEN viruses have been considered as candidate vaccines but inconsistent neutralizing antibody responses as well as occasional genetic instability of the variants have raised doubts about their usefulness (Bancroft et al., 1984; Eckels et al., 1984). The chemical synthesis of viral polypeptides or their preparation by recombinant DNA methods may provide novel alternatives for the development of a satisfactory DEN vaccine. The choice of viral proteins for incorporation into such a vaccine will depend on their capacity to stimulate a protective immune response. Although immunity to flavivirus infection has generally been related to the presence of neutralizing antibodies against the virion envelope glycoprotein, we have recently shown that immunization with a yellow fever virus (YF) non-structural (NS) glycoprotein, gp48, protects mice and monkeys against lethal YF infection (Schlesinger et al., 1985, 1986). This protein, currently designated NS1 (Rice et al., 1985), is highly conserved among flaviviruses and is the soluble complement-fixing (CF) antigen which is expressed on the surface of DEN-infected cells (Cardiff &Lund, 1976; Smith & Wright, 1985). The present report describes antigenic characteristics of dengue 2 virus (DEN 2) NS1 and protection against intracerebral DEN 2 challenge in mice immunized with this protein. Immunoaffinity-purified NS1 was prepared from lysates of DEN 2 (New Guinea-C)-infected Vero cells by modification of a previously described column chromatography method (Schlesinger et al., 1985). Briefly, infected cells grown in roller bottles or in suspension culture on Cytodex beads (Pharmacia) were solubilized in a non-denaturing buffer containing 0.l M-Tris- HC1 ph 7.5, 0.15 M-NaCI, 1~ Triton X-100, 1~o NP40, and 1 mm-phenylmethysulphonyl SGM
2 854 Short communication (a) 1 2 (b) U 68-- U m --E 45- ~ ~ ~ ~.~ --NS1 Fig. 1. (a) Silver stain of purified DEN 2 NS1. Proteins were electrophoresed on an IlK SDSpolyacrylamide gel. Lane 1, mol. wt. markers; lane 2, 10 gg DEN 2 NS1. (b) Immunoprecipitation of [35S]methionine-labelled DEN 2-specific proteins. Labelled DEN 2-infected Vero cell lysates were precipitated with sera from ovalbumin-immunized mice (lane 1), sera from NSl-immunized mice (lane 2), anti-den 2 NS1 monoclonal antibody 9A9 (lane 3) or mouse anti-den 2 hyperimmune ascites (lane 4). fluoride. Monoclonal antibodies directed against DEN 2 NS1 were partially purified by ammonium sulphate precipitation from mouse ascitic fluid and coupled to cyanogen bromideactivated Sepharose 4B beads for use as a ligand. Two hybridomas (9A9, 9G5) secreting IgG1 antibody against DEN 2 NSI were produced by fusing non-secretor X63-Ag8-653 myeloma cells with spleen cells from BALB/c mice immunized with DEN 2 (New Guinea-C)-infected suckling mouse brain (SMB). An additional anti-den 2 NS 1 IgG 1 monoclonal antibody, D7-3E9-4, and an anti-den 2 envelope protein monoclonal antibody, 4G2, prepared against the New Guinea- C strain of DEN 2 (Gentry et al, 1982), were provided by Dr M. K. Gentry (WRAIR, Washington, D.C., U.S.A.). NS1 was eluted with 0-1 u-glycine buffer ph 2-5 and samples were immediately buffered to ph 7.0 with Tris-HCl followed by exhaustive dialysis against phosphate-buffered saline (PBS) ph 7.4. Fractions were analysed for NS1 by SDS-PAGE followed by silver staining (Bio-Rad). The protein content of pooled samples was estimated by a Coomassie Brilliant Blue technique (Bio-Rad) using bovine serum albumin as a standard. DEN 2 NS1 migrated as a single band of approximately mol. wt. after SDS-PAGE (Fig. 1 a). To evaluate the protective capacity of NS1 immunization, 3-week-old Swiss CD1 mice (Charles River Breeding Laboratories, Wilmington, Mass., U.S.A.) were injected intraperitoneally (i.p.) with 20 gg purified NS1 emulsified in complete Freund's adjuvant followed by a second i.p. injection of 20 gg NS1 in PBS 2 weeks later. Control mice were injected with 20 p.g ovalbumin in the same schedule. An additional control group of 3-week-old mice was immunized with a single i.p. dose of 1 x 106 p.f.u. DEN 2 (New Guinea-C) grown in C6/36 Aedes albopictus cells. DEN 2 (New Guinea-C) passaged 35 times in SMB was provided as a
3 Short communication Table 1. Protection of mice against intracerebral challenge with DEN 2 by vaccination with DEN 2 NS1 Pre-challenge serum titre (reciprocal) A Antigen* Complementfixation Neutralization No. paralysed/ total No. dead/total DEN 2 (New Guinea-C) < /10 1/10 NSl/CFA OA/CFA 256 < 8 <20t < 20 6/33:~ 18/34 4/33~ 14/34 * Mice were given a single i.p. dose of 106 p.f.u. DEN 2 (New Guinea-C) or primed with 20 p.g NS1 or ovalbumin (OA) in complete Freund's adjuvant (CFA) and boosted with 20 gg of each protein in solution. t There was no plaque reduction at 1/20 serum dilution. :~ P < 0-02, Chi square. NSl-immunized against OA-immunized. 855 Table 2. Binding of anti-den antibodies to DEN 2 NS1 Immune ascites* At Polyclonal DEN 1 (Hawaii) DEN 2 (New Guinea-C) DEN 3 (PR6) DEN 4 (H241) Monoclonal anti-den 2 NS1 Monoclonal 9A anti-den E 4G * 1/100 final dilution of mouse immune ascites. t Bound alkaline phosphatase-labelled rabbit anti-mouse IgG. homogenate of virus-infected SMB by Dr W. E. Brandt (Fort Detrick, Frederick, Md., U.S.A.) and was passaged once in C6/36 A. albopictus cells for immunization of mice or used directly to challenge mice at 6 weeks of age. Mice were inoculated intracerebrally with 0.04 ml of a 1/100 dilution of virus-infected SMB, which was the dose determined to result in the highest morbidity and mortality in 6-week-old mice. Mice were bled from the orbit the day before challenge and the sera of each group were pooled. The results of challenge after immunization with infectious DEN 2, purified NS1 or negative ovalbumin control are shown in Table 1. Mice immunized with infectious DEN 2 developed neutralizing antibody (90~o plaque reduction in Vero cells at 1/640) and were protected. The proportion of mice that developed hindleg paralysis and died was significantly (P < 0.02) reduced by NS1 immunization. Sera taken pre-challenge from these mice were monospecific for NS1 as determined by radioimmunoprecipitation and SDS- PAGE (Fig. I b) and gave no plaque reduction but fixed complement in high titre (1/256) against SMB-derived DEN 2 antigen (Casey, 1965); there was little or no complement-fixing activity against other serotypes of DEN (DEN 1:1/8; DEN 3, 4: < 1/8). High titre neutralizing antibody (1/640) was present in the serum of surviving mice 5 weeks after challenge, indicating that virus replication had occurred. An antigenic determinant common to all four DEN serotypes has been shown by crossabsorption studies to be present on the DEN soluble complement-fixing antigen, e.g. NS1 (Russell et al., 1970). To test for the presence of DEN antigenic sites on NS 1, the relative binding to NS1 of DEN serotype-specific antibodies was measured by a conventional ELISA. The results are summarized in Table 2. Hyperimmune ascitic fluids prepared against all four DEN serotypes bound to NS1. A monoclonal anti-nsl antibody also bound whereas a monoclonal antibody against the DEN 2 envelope glycoprotein (E) did not. Concordant with these results, rabbits hyperimmunized with DEN 2 NS1 developed complement-fixing antibody in high titre against representative strains of each DEN serotype
4 856 Table 3. Short communication Complement-fixation titres (CF) after immunization of rabbits with DEN 2 New Guinea-C NSI* Suckling mouse brain (SMB) antigen DEN 1 DEN 2 DEN 3 DEN 4 Normal Hawaii NG-C H87 H241 SMB Rabbit no. 1 Pre-immunization CF 8t Post-immunization CF Rabbit no. 2 Pre-immunization CF Post-immunization CF * Rabbits were primed by combined intradermal and subcutaneous injections of about 20 ~tg DEN 2 NS1 in complete Freund's adjuvant (FA) and boosted three times with about 10 ~tg NS1 in incomplete FA at monthly intervals. Serum was collected 1 week after the last boost. Pre-immunization sera were slightly anticomplementary. t Reciprocal. (Table 3). These results suggested that immunization with DEN 2 NS1 might confer crossprotection against challenge with other serotypes of DEN but no such protection was observed among mice immunized with DEN 2 N S 1 following intracerebral challenge with neurovirulent Hawaii strain DEN 1 (provided by Dr R. E. Shope, YARU, New Haven, Conn., U.S.A.). We have shown that immunization with the DEN 2 glycoprotein NS1 confers partial protection in mice against DEN 2 encephalitis in the absence of detectable anti-virion antibody as measured by neutralization and immunoprecipitation assays. These results extend our earlier observation that immunization with YF NS 1 protects mice against YF encephalitis but differ in that protection by YF NS1 immunization was complete. Immunization with DEN 2 NS1 stimulated production of high-titred monospecific complement-fixing antibody. Such antibody might protect by promoting complement-mediated lysis of infected cells bearing surface NS 1. In earlier studies, the capacity of passively transferred anti-yf NS1 antibodies to protect mice against intracerebral YF inoculation correlated with their ability to fix complement and to lyse virus-infected cells (Schlesinger et al., 1985). It was, therefore, not surprising that mice passively immunized with the available non-complement-fixing IgG1 monoclonal antibodies to DEN 2 NSI were not protected (data not shown). Consistent with the results of an earlier cross-absorption study of DEN soluble complementfixing antigen (Russell et al., 1970), an antigenic site(s) common to each of the four DEN serotypes was demonstrated on NS1 by ELISA. Hyperimmunization of rabbits with DEN 2 NS1 stimulated production of antibody with broad DEN serotype reactivity but DEN 2 NS1 immunization failed to provide cross-protection in mice, perhaps because adequate levels of heterotypic complement-fixing antibodies did not appear in the relatively short interval between immunization and challenge. It has been shown that antibodies to DEN virion in subneutralizing concentrations may enhance replication of the virus in macrophages and it has been proposed that antibodies to one DEN serotype may predispose to more severe disease in the event of later infection with a different DEN serotype (Halstead & O'Rourke, 1977). Since immunization with DEN 2 NS1 does not elicit detectable anti-virion antibodies, enhancement of a subsequent dengue infection would be unlikely, The results of the present study suggest that further investigation of DEN NS1 as a potential vaccine component is warranted. It is possible that sequential vaccination with DEN NS1 and active DEN might result in subclinical infection with viral replication, production of neutralizing antibody and subsequent immunity. We thank Susan Chapman and Ronald Robinson for technical assistance, Dr Charles Calisher (Centers for Disease Control) for complement-fixation assays, and Joanne Prives for transcription of the manuscript. This work was funded in part by Grant GA HS 5852 from the Rockefeller Foundation and Grant V22/181/8 from the World Health Organization.
5 Short communication 857 REFERENCES BANCROFT, W. H., SCOTT, R. McN., ECKELS, K. H., HOKE, C. H., JR, SIMMS, T. E., JESRANI, K. D. T., SUMMERS, P. L., DUBOIS, D. R., TSOULOS, D. & RUSSELL, P. K. (1984). Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. Journal of lnfectious Diseases 149, CARDIFF, R. D. & LUND, J. K. (1976). Distribution of dengue-2 antigens by electron immunocytochemistry. Infection and Immunity 3, CgSEY, 8. L. (1965). Standardized diagnostic complement-fixation method and adaptation to micro test. Public Health Monograph No. 74. U.S. Public Health Service Publication No ECKELS, K. H., SCOTT, R. McN., BANCROFT, W. H., BROWN, J., DUBOIS, D. R., SUMMERS, P. L., RUSSELL, P. K. & HALSTEAD, s. B. (1984). Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. American Journal of Tropical Medicine and Hygiene 33, GENTRY, M. K., HENCHAL, E. A., McCOWN, J. M., BRANDT, W. E. & DALRYMPLE, J. M. (1982). Identification of distinct antigenic determinants on dengue-2 virus by using monoclonal antibodies. American Journal of Tropical Medicine and Hygiene 33, HALSTEAD, S. B. (1980). Dengue haemorrhagic fever - a public health problem and a field for research. Bulletin of the World Health Organization.58, HALSTEAD, S. B. & O'ROURKE, E. J. (1977). Dengue viruses and mononuclear phagocytes. Journal of Experimental Medicine 146, RICE, C. M., LENCHES, E. M., EDDY, S. R., SHIN, S. J., SHEETS, R. L. & STRAUSS, J. H. (1985). Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229, RUSSELL, P. K., CHIEWSLW, V. & BRANDT, W. E. (1970). Immunoprecipitation analysis of soluble complement-fixing antigens of dengue viruses. Journal of Immunology 105, SABIN, A. B. & SCHLESINGER, R. W. (1945). Production of immunity to dengue with virus modified by propagation in mice. Science 101, SCHLESINGER, J. J., BRANDRISS, M. W. & WALSH, E. E. (1985). Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. Journal oflmmunology 135, SCHLESINGER, J. J., BRANDRISS, M. W., CROPP, C. B. & MONATH, T. P. (1986). Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural NS1. Journal of Virology 60, SCHLESINGER, R. W., GORDON, I., FRANKEL, J. W., WINTER, J. W., PATTERSON, P. R. & DORRANCE, W. R. (1956). Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. Journal of Immunology 77, SMITH, G. W. & WRIGHT, P. J. (1985). Synthesis of proteins and glycoproteins in dengue type 2 virus-infected Vero and Aedes albopietus cells. Journal of General Virology 66, (Received 4 September 1986)
Synergistic Interactions of Anti-NSl Monoclonal Antibodies Protect Passively Immunized Mice from Lethal Challenge with Dengue 2 Virus
J. gen. Virol. (1988), 69, 2101-2107. Printed in Great Britain 2101 Key words: dengue 2 virus/flaviviruses/passive protection Synergistic Interactions of Anti-NSl Monoclonal Antibodies Protect Passively
More informationAntibody-dependent Enhancement of Tick-borne Encephalitis Virus Infectivity
J. gen. Virol. (1985), 66, 1831-1837. Printed in Great Britain 1831 Key words: antibody-mediated enhancement/tbev/flavivirus Antibody-dependent Enhancement of Tick-borne Encephalitis Virus Infectivity
More informationMonoclonal Antibodies Specifiec for Dengue Virus Type 3
JOURNAL OF CLINICAL MICROBIOLOGY, July 1980, p. 74-78 0095-1137/80/07-0074/05$02.00/0 Vol. 12, No. 1 Monoclonal Antibodies Specifiec for Dengue Virus Type 3 DAVID DITTMAR, HAROLD G. HAINES, AND ALBERT
More informationGenetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence
JOURNAL OF VIROLOGY, Feb. 1998, p. 1647 1651 Vol. 72, No. 2 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus
More informationCustom Antibodies Services. GeneCust Europe. GeneCust Europe
GeneCust Europe Laboratoire de Biotechnologie du Luxembourg S.A. 2 route de Remich L-5690 Ellange Luxembourg Tél. : +352 27620411 Fax : +352 27620412 Email : info@genecust.com Web : www.genecust.com Custom
More information1 Name. 1. (3 pts) What is apoptosis and how does it differ from necrosis? Which is more likely to trigger inflammation?
1 Name MCB 150 Midterm Eam #1 (100 points total) Please write your full name on each page of the eam!! The eam consists of 17 questions (6 pages). Each has a different point count as indicated. Please
More informationSolutions for Your Research
Solutions for Your Research Custom Antibody Services Polyclonal Monoclonal The service we offer is very complete starting from rabbits, mice and rats. The different formats provided by Primm depend on
More informationNational Institute of Virology(NIV), Pune
National Institute of Virology(NIV), Pune Japanese Encephalitis Vaccine Product/Process: Chimeric peptide vaccine candidate against Japanese Encephalitis virus. Application/Uses: Japanese encephalitis
More informationExamination in Immunotechnology, 30 May 2011, 8-13
Examination in Immunotechnology, 30 May 2011, 8-13 1 Each question can give 5p, with a total of 10 questions (i.e. 50 points in total). 2 Write name and personal number on ALL pages (including the cover).
More informationPassive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus
Journal of General Virology (1990), 71, 745-748. Printed in Great Britain 745 Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus
More informationSupplementary Figure 1: Sequence alignment of partial stem region of flaviviruses
Supplementary Figure 1: Sequence alignment of partial stem region of flaviviruses E prtoeins. Polyprotein sequences of viruses were downloaded from GenBank and aligned by CLC Sequence Viewer software.
More informationDengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development
JOURNAL OF VIROLOGY, Nov. 2003, p. 11436 11447 Vol. 77, No. 21 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.21.11436 11447.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Dengue
More informationYellow Fever Vaccine (Live) is a freeze-dried preparation of the 17D strain of yellow fever virus grown in fertilised hen eggs.
YELLOW FEVER VACCINE Yellow Fever Vaccine (Live) is a freeze-dried preparation of the 17D strain of yellow fever virus grown in fertilised hen eggs. Production General provisions The production of vaccine
More informationChapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More information1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationYellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties
JOURNAL OF VIROLOGY, Apr. 1999, p. 3095 3101 Vol. 73, No. 4 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Yellow Fever/Japanese Encephalitis Chimeric Viruses:
More informationF4/80, CD11b, Gr-1, NK1.1, CD3, CD4, CD8 and CD19. A-antigen was detected with FITCconjugated
SDC MATERIALS AND METHODS Flow Cytometric Detection of A-Antigen Expression Single cell suspensions were prepared from bone marrow, lymph node and spleen. Peripheral blood was obtained and erythrocytes
More informationAb SpinTrap Ab Buffer Kit
GE Healthcare Data File 28-9020-30 AB Protein Sample Preparation Ab SpinTrap Ab Buffer Kit The Ab SpinTrap and the Protein G HP SpinTrap are identical columns. The difference between the article numbers
More informationMonoclonal Antibodies to the S1 Spike and Membrane Proteins of Avian Infectious Bronchitis Coronavirus Strain Massachusetts M41
J. gen. Virol. (1984), 65, 2281-2286. Printed in Great Britain 2281 Key words: coronavirus/ibv/monoclonal antibodies Monoclonal Antibodies to the S1 Spike and Membrane Proteins of Avian Infectious Bronchitis
More informationDengue Vaccine Development. Status, challenges, and WHO priorities. 24/05/2004 WHO Initiative for Vaccine Research
Dengue Vaccine Development Status, challenges, and WHO priorities Key issues Vaccination appears as the only sustainable strategy for disease prevention, no vaccine available until today; Circulation of
More informationMonoclonal Antibody Generation. Ivo Lorenz Tri-Institutional Therapeutics Discovery Institute
Monoclonal Antibody Generation Ivo Lorenz Tri-Institutional Therapeutics Discovery Institute Common Antibody Formats Heavy chain VL VH Light chain Fab CL CH1 VH VL Linker CH2 VH VL Fc CH3 IgG Immunoglobulin
More informationNon-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge
Journal of General Virology (2006), 87, 339 346 DOI 10.1099/vir.0.81256-0 Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge
More informationCONTRACTING ORGANIZATION: Albert Einstein College of Medicine Bronx, NY 10461
AD Award Number: W81XWH-08-1-0011 TITLE: Defining B. Anthracis Protective Antigen Antigenic Domains PRINCIPAL INVESTIGATOR: Arturo Casadevall, M.D., Ph.D. CONTRACTING ORGANIZATION: Albert Einstein College
More informationT-cell response. Taken from NIAID: s.aspx
T-cell receptor T-cell response 1. Macrophage or dendritic cell digest antigen bacteria, virus 2. Fragments of Ag bind to major histo-compatiblity (MHC) proteins in macrophage. 3. MHC I-Ag fragment expressed
More information(Accepted 20 April 1989)
J. gen. Virol. (1989), 7, 2185-219. Printed in Great Britain 2185 Key words: RSV/vaccinia virus/antibody-mediated immune suppression Immunosuppression of the Antibody Response to Respiratory Syncytial
More informationMonoclonal antibodies specific for the G1 glycoprotein of La Crosse virus that react with other California serogroup viruses
Journal of General Virology (1990), 71, 523-530. Printed in Great Britain 523 Monoclonal antibodies specific for the G1 glycoprotein of La Crosse virus that react with other California serogroup viruses
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationDetection of Virus-specific Antigen in the Nuclei or Nucleoli of Cells Infected with Zika or Langat Virus
J. gen. Virol. (1988), 69, 1913-1920. Printed in Great Britain 1913 Key words: Zika virus/langat virus/monoclonal antibodies Detection of Virus-specific Antigen in the Nuclei or Nucleoli of Cells Infected
More informationGrouping of Feline Calicivirus Field Isolates Using Monoclonal Antibodies
SHORT REPORT Grouping of Feline Calicivirus Field Isolates Using Monoclonal Antibodies Tomoko TAJIMA, Erika NAKATA, Yukinobu TOHYAI1), Kazuyo YURI2), Hiromi KATAE2), and Takeshi MIKAMI3) Department of
More informationImpacts / Baseline data Project title: A dual recombinant vaccine for brucellosis and immunocontraception in feral swine
Impacts / data Project title: A dual recombinant vaccine for brucellosis and immunocontraception in feral swine Please use the table below to guide you on reporting your impacts or baseline data from your
More informationProtein A Agarose Immunoprecipitation Kit
Protein A Agarose Immunoprecipitation Kit Catalog Number KA0568 20 Reactions Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information...
More informationDEFENSE TECHNICAL INFORMATION CENTER
DEFENSE TECHNICAL INFORMATION CENTER Inforttniwufor the. OtftKit- Ct»**uoiUy DTIC has determined on /ffi fc/ /,ty/g?y that this Technical Document has the Distribution Statement checked below. The current
More informationImmunoprecipitation (IP)
BlueGene Biotech Co.,Ltd. Tel: 0086-21-61471242 Fax: 0086-21-61471242 ext 806 E-mail: sales@bluegene.cc tech@bluegene.cc www.elisakit.cc www.bluegene.cc Immunoprecipitation (IP) Immunoprecipitation is
More informationReceived 30 August 2002/Accepted 11 December 2002
JOURNAL OF VIROLOGY, Mar. 2003, p. 3655 3668 Vol. 77, No. 6 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.6.3655 3668.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Yellow Fever
More information1 R21 AI A1 2 VMD HALFORD, W
1 R21 AI081072-01A1 2 VMD 1R21AI081072-01A1 ILLIAM RESUME AND SUMMARY OF DISCUSSION: The proposed study is to develop safe and effective live attenuated vaccines against herpes simplex virus 2 by using
More informationFIXING ANTIGEN) FINAL REPORT JACOB J. SCHLESINGER MICHAEL W. BRANDRISS. Supported by
t, Ow) IMMUNOGENIC CHARACTERIZATION OF THE DENGUE VIRUS 00 SPECIFIED NONSTRUCTURAL GLYCOPROTEIN gp48 (NV3, SOLUBLE NCOMPLEMENT FIXING ANTIGEN) FINAL REPORT AD JACOB J. SCHLESINGER MICHAEL W. BRANDRISS
More informationChapter 3. Clonal selection
Chapter 3. Clonal selection I have called this principle, by which each slight variation, if useful, is preserved, by the term of Natural Selection -Charles Darwin, On the Origin of Species, 1859 4 The
More informationThe Herpes Simplex Virus Type 2 Alkaline DNase Activity Is Essential for Replication and Growth
J. gen. Virol. (1986), 67, 1173-1178. Printed in Great Britain 1173 Key words: HSV-2/DNase activity/dna synthesis~growth The Herpes Simplex Virus Type 2 Alkaline DNase Activity Is Essential for Replication
More informationApplication Note AN001
Testing hybridoma supernatants with the Spots On Dots Antibody Screening Kit Application Note AN1 Table of Contents Overview... 2 Figure 1. Screening of hybridomas raised against peptide antigens... 3
More informationSerology as a Diagnostic Technique
Serology as a Diagnostic Technique Characteristics of Any Diagnostic Techniques Any useful detection strategy must be: Specific: yield a positive response for only the target organism or molecule. Sensitive:
More informationSolutions to 7.02 Quiz II 10/27/05
Solutions to 7.02 Quiz II 10/27/05 Class Average = 83 Standard Deviation = 9 Range Grade % 87-100 A 43 74-86 B 39 55-73 C 17 > 54 D 1 Question 1 (56 points) While studying deep sea bacteria, you discover
More informationMCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam will have 40 multiple choice questions.
MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam 1 2018 will have 40 multiple choice questions. READ ALL THE CHOICES AND SELECT THE BEST 1. Which of the following
More informationa. Hypoxanthine was present in the media. MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No.
MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam 1 2018 will have 40 multiple choice questions. READ ALL THE CHOICES AND SELECT THE BEST 1. Which of the following
More informationIMMUNOPRECIPITATION (IP)
1 IMMUNOPRECIPITATION (IP) Overview and Technical Tips 2 CONTENTS 3 7 8 9 12 13 17 18 19 20 Introduction Factors Influencing IP General Protocol Modifications Of IP Protocols Troubleshooting Contact Us
More informationFoot-and-Mouth Disease Virus: Selection by
INFECTION AND IMMUNITY, Jan. 1972, p. 65-69 Copyright 1972 American Society for Microbiology Foot-and-Mouth Disease Virus: Selection by Homogenized Calf Kidney Adsorption and Cell Culture Passage Vol.
More informationRAT MONOCLONAL ANTIBODIES ANTI-MOUSE IMMUNOGLOBULINS
RAT MONOCLONAL ANTIBODIES ANTI-MOUSE IMMUNOGLOBULINS Supplied by: dianova GmbH Warburgstrasse 45 20354 Hamburg Phone: +49 (0)40 45 06 70 Email: info@dianova.de www.dianova.com MOUSE IMMUNOGLOBULINS 1 (Sub)classes
More informationSouthernBiotech Custom Services
SouthernBiotech Custom Services Quality Antibodies for Quality Research Peptide Synthesis for Antibody Production SouthernBiotech provides complete services for production of immunogenic peptides for antibody
More informationCHAPTER 24. Immunology
CHAPTER 24 Diagnostic i Microbiology and Immunology Growth-Dependent Diagnostic Methods Isolation of Pathogens from Clinical Specimens Proper sampling and culture of a suspected pathogen is the most reliable
More information8 th Vaccine & ISV Congress October 2014 Philadelphia, USA
8 th Vaccine & ISV Congress 26-28 October 2014 Philadelphia, USA 2014 Guinea Ebola Virus Recombinant Glycoprotein (GP) Nanoparticle Vaccine was Highly Immunogenic and Cross- Neutralized 1976 Ebola Virus
More informationTHE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT IN THE BLOOD
Published Online: 1 February, 1941 Supp Info: http://doi.org/10.1084/jem.73.2.191 Downloaded from jem.rupress.org on November 21, 2018 THE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT
More informationAtsushi Yamanaka, Saori Kosugi, and Eiji Konishi*
JOURNAL OF VIROLOGY, Jan. 2008, p. 927 937 Vol. 82, No. 2 0022-538X/08/$08.00 0 doi:10.1128/jvi.00992-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Infection-Enhancing and
More informationThe Dengue Vaccine Landscape. In-Kyu Yoon, M.D. Director, Dengue Vaccine Initiative International Vaccine Institute Seoul, Korea
The Dengue Vaccine Landscape In-Kyu Yoon, M.D. Director, Dengue Vaccine Initiative International Vaccine Institute Seoul, Korea 1 Dec 2015 Dengue Vaccine Initiative (DVI) John Hopkins University School
More informationImmunological Applications. Chapter 8: Background
Immunological Applications Chapter 8: Background The Immune System Types of Immunity Innate The natural immunity present at birth Acquired A specific response to foreign substances. Some cells remember
More informationPr oject Summar y. Development of a diagnostic assay for chronic wasting disease. Principal Investigator: Richard Rubenstein
Pr oject Summar y Development of a diagnostic assay for chronic wasting disease Principal Investigator: Richard Rubenstein New York State Institute for Basic Research Study Completed May 2003 Funded by
More informationStreptavidin Mag Sepharose
GE Healthcare Life Sciences Data file 28-9921-05 AB Protein sample preparation Streptavidin Mag Sepharose Streptavidin Mag Sepharose (Fig 1) is a magnetic bead for simple and efficient enrichment of target
More informationCASE STUDY 4 Swine Erysipelas vaccine In vitro ELISA assay to replace in vivo immunization-challenge test. P-J Serreyn
CASE STUDY 4 Swine Erysipelas vaccine In vitro ELISA assay to replace in vivo immunization-challenge test P-J Serreyn Introduction History and background Situation & Methods in EU Companies Authorities
More informationMETHODS IN CELL BIOLOGY EXAM II, MARCH 26, 2008
NAME KEY METHODS IN CELL BIOLOGY EXAM II, MARCH 26, 2008 1. DEFINITIONS (30 points). Briefly (1-3 sentences, phrases, word, etc.) define the following terms or answer question. A. depot effect refers to
More informationThe antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coil
Journal of General Virology (1990), 71, 2107-2114. Printed in Great Britain 2107 The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coil Peter W. Mason, 1
More informationNeutralizing epitopes of the serotypes of bluetongue virus present in the United States
Journal of General Virology" (1992), 73, 1947-1952. Printed in Great Britain 1947 Neutralizing epitopes of the serotypes of bluetongue virus present in the United States Paul V. Rossitto and N. James MacLachlan*
More informationAntigenic Relationships among Autonomous Parvoviruses
J. gen. Virol. (1986), 67, 2839-2844. Printed in Great Britain 2839 Key words: antigenic relationships/autonomous parvoviruses Antigenic Relationships among Autonomous Parvoviruses ByW. L. MENGELING, l*
More informationRecombinant, Insect Cell-Derived RSV Nanoparticle Vaccine
Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine Gregory Glenn Chief Medical Officer MVADS-Copenhagen 4 July 2012 1 Agenda for RSV Discussion Overview of Insect Cell Technology Respiratory Syncytial
More informationMATF Antigen Submission Details and Standard Project Deliverables
MATF Antigen Submission Details and Standard Project Deliverables What we require when you submit your antigen: Proteins For a recombinant protein target, we require a minimum of 400µg soluble recombinant
More information91 005oo II lllt!!lll
AD-A238 967 0 12, 1991OAJIk July 12, 1991 Grant No: N00014-89-J-3073 Trimester Report 3/15/91-7/12/91 P.I. H. Shaw Warren, M.D. Massachusetts General Hospital FLEC1 TE Boston, MA 02114 JUL 301991j i. Work
More informationADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine. Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr.
ADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr. 1 Herpes Simplex Viruses Predominantly infect epithelial cells; establish
More informationFigure S1. Verification of ihog Mutation by Protein Immunoblotting Figure S2. Verification of ihog and boi
Figure S1. Verification of ihog Mutation by Protein Immunoblotting Extracts from S2R+ cells, embryos, and adults were analyzed by immunoprecipitation and immunoblotting with anti-ihog antibody. The Ihog
More informationMonoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells
JOURNAL OF VIROLOGY, Aug. 2001, p. 7769 7773 Vol. 75, No. 16 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.16.7769 7773.2001 Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are
More informationGα 13 Activation Assay Kit
A helping hand for your research Product Manual Configuration-specific Monoclonal Antibody Based Gα 13 Activation Assay Kit Catalog Number: 80401 20 assays NewEast Biosciences 1 Table of Content Product
More informationCat. # MK138. For Research Use. Rat IgG EIA Kit. Product Manual. v1012
Cat. # MK138 For Research Use Product Manual Table of Contents I. Description... 3 II. Principle... 3 III. Kit Components... 4 IV. Materials Required but not Provided... 4 V. Storage... 4 VI. Intended
More informationFor Research Use Only. Not for use in diagnostic procedures.
Printed December 13, 2011 Version 1.0 For Research Use Only. Not for use in diagnostic procedures. DDDDK-tagged Protein PURIFICATION GEL with Elution Peptide (MoAb. clone FLA-1) CODE No. 3326 / 3327 PURIFICATION
More informationCat. No. MG17PG-1ml XPRESSAFFINITY PROTEIN G- MAGNETIC NANOPARTICLES (MNP) FOR RESEARCH APPLICATIONS
Cat. No. MG17PG-1ml XPRESSAFFINITY PROTEIN G- MAGNETIC NANOPARTICLES (MNP) FOR RESEARCH APPLICATIONS Product Description: MagGenome s Protein G-MNP provides a fast and convenient method for affinity based
More informationProduct Data Sheet - ANTIBODY
888.267.4436 techsupport@origene.com www.origene.com Name:Mouse Monoclonal MBP Antibody (2H9) Product Data Sheet - ANTIBODY Catalog: TA336919 Components: Mouse Monoclonal MBP Antibody (2H9) (TA336919)
More informationAntibodies against PCNA were previously described [1]. To deplete PCNA from Xenopus egg
Supplementary information Supplementary methods PCNA antibody and immunodepletion Antibodies against PCNA were previously described [1]. To deplete PCNA from Xenopus egg extracts, one volume of protein
More informationEvaluation of the C6/36 Aedes albopiatus Cell Line as a Substrate for Dengue Virus Growth
Viruses: Evaluation of the C6/36 Aedes albopiatus Cell Line as a Substrate for Dengue Virus Growth Principal Investogators : Ananda Nisalak, MoDo Donald S. Burke, MAJ, MC Assistant Investigators ~ NaowayUbol
More informationSUPPLEMENTAL MATERIAL. Supplemental Methods:
SUPPLEMENTAL MATERIAL Supplemental Methods: Immunoprecipitation- As we described but with some modifications [22]. As part of another ongoing project, lysate from human umbilical vein endothelial cells
More informationJOURNAL OF VIROLOGY, July 1999, p Vol. 73, No. 7. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, July 1999, p. 5527 5534 Vol. 73, No. 7 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. The Anamnestic Neutralizing Antibody Response Is
More informationCdc42 Activation Assay Kit
A helping hand for your research Product Manual Configuration-specific Monoclonal Antibody Based Cdc42 Activation Assay Kit Catalog Number: 80701 20 assays 1 Table of Content Product Description 3 Assay
More informationINSECT CELL/BACULOVIRUS PRODUCTION
INSECT CELL/BACULOVIRUS PRODUCTION PEF # GENE NAME TRANSFER VECTOR BEVS MOLECULAR WEIGHT 2015-XXXX XXXX pbac1 flashbacultra TM 36.0 kda EXPRESSION METHOD OVERVIEW: Insect cells Spodoptera frugiperda (Sf9)
More informationAnnual Report. Maurille J. Fournier Thomas L. Mason. February 1, Supported by
IT FILE COP AD STRUCTURE AND EXPRESSION OF GENES FOR FLAVIVIRLS IMMUNOGENS Annual Report 0 Maurille J. Fournier Thomas L. Mason February 1, 1988 Supported by U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT
More informationRabbit Anti-Mouse/Rat Asialo GM1 Polyclonal Antibody
Rabbit Anti-Mouse/Rat Asialo GM1 Polyclonal Antibody CL8955 LOT: KQF6371 DESCRIPTION: Cedarlane s Anti-Asialo GM1 polyclonal antibody reacts with mouse and rat Natural Killer (NK) cells. It also exhibits
More informationMonoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica
VIROLOGY 246, 317 328 (1998) ARTICLE NO. VY989200 Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica John T. Roehrig, 1 Richard A. Bolin, and Robert G. Kelly Arbovirus
More informationCHAPTER 5: TECHNIQUES IN PROTEIN BIOCHEMISTRY
CHAPTER 5: TECHNIQUES IN PROTEIN BIOCHEMISTRY CHEM 527 September 13, 2012 An understanding of the proteome is acquired by isolating, characterizing and cataloging proteins. In some, but not all, cases,
More informationLaboratory Service Report
Laboratory Service Report 1-00-533-1710 SA0004515 SA0004515 Client SA0004515 0/14/2012 13:00 C702-DLP ROCHESTER 0/17/2012 14:39 eningoencephalitis Comp Panel, S REPORTED 0/16/2012 14:26 Lymphocytic Choriomeningitis
More informationProtocol Immunprecipitation
1 Protocol Immunprecipitation IP Juni 08, S.L. Before starting an IP on should be certain, that one can clearly detect the Protein to precipitate in a standard Western Blot with the lysis conditions used
More informationProduct Data Sheet - TRUEMAB
Name:Mouse monoclonal anti-pcna antibody, clone 4B2, Loading, clone OTI4B2 (formerly 4B2) Product Data Sheet - TRUEMAB 888.267.4436 techsupport@origene.com www.origene.com Catalog: TA800880 Components:
More informationPASSIVE PROTECTION BY HUMAN SERUM IN MICE INFECTED WITH ENCAPSULATED STAPHYLOCOCCUS A UREUS
PASSIVE PROTECTION BY HUMAN SERUM IN MICE INFECTED WITH ENCAPSULATED STAPHYLOCOCCUS A UREUS K. YOSHIDA, Y. ICHIMAN, S. NARIKAWA, M. TAKAHASHI, E. KONO* AND C. L. SAN CLEMENTE? Department of Microbiology
More informationArf6 Activation Assay Kit
A helping hand for your research Product Manual Configuration-specific Monoclonal Antibody Based Arf6 Activation Assay Kit Catalog Number: 82401 20 assays NewEast Biosciences 1 Table of Content Product
More informationAntibodies to Animal Cells and Serum Proteins
ANTIBODIES TO ANIMAL CELLS AND SERUM PROTEINS Antibodies to Animal Cells and Serum Proteins Antibodies to Animal Cellular Antigens Antibodies to Mouse Brain Antibodies to Animal Serum Proteins INTERNATIONAL
More informationSuperexpression of tuberculosis antigens in plant leaves
Superexpression of tuberculosis antigens in plant leaves Tuberculosis Volume 87, Issue 3, May 2007, Pages 218-224 Yuri L. Dorokhov, a,, Anna A. Shevelevaa, Olga Y. Frolovaa, Tatjana V. Komarovaa, Anna
More informationLOABeads PrtA Magnetic bead purification of antibodies Capacity 45 mg IgG/ml
LOABeads PrtA Magnetic bead purification of antibodies Capacity 45 mg IgG/ml Product Manual Lab on a Bead AB Revision date 2018-05-23 Copyright 2015-2018 Lab on a Bead AB All rights reserved Table of Contents
More informationBACTERIAL PRODUCTION EXPRESSION METHOD OVERVIEW: PEF # GENE NAME EXPRESSION VECTOR MOLECULAR WEIGHT kda (full-length) 34.
BACTERIAL PRODUCTION PEF # GENE NAME EXPRESSION VECTOR MOLECULAR WEIGHT 2015-XXXX XXXX pet-32a 50.9 kda (full-length) 34.0 kda (cleaved) EXPRESSION METHOD OVERVIEW: Plasmid DNA was transformed into BL21
More informationProtein A Mag Sepharose Xtra Protein G Mag Sepharose Xtra
GE Healthcare Data file 28-9768-1 AA Protein sample preparation Protein A Mag Sepharose Xtra Xtra products are magnetic beads designed for efficient, high capacity small-scale purification/screening of
More informationAn indirect haemagglutination test to detect serum antibodies to Giardia lamblia
J. Biosci., Vol. 10, Number 4, December 1986, pp. 475-480. Printed in India. An indirect haemagglutination test to detect serum antibodies to Giardia lamblia K. N. JALAN, TUSHER MAITRA and RITA DAS Kothari
More informationRheB Activation Assay Kit
A helping hand for your research Product Manual Configuration-specific Monoclonal Antibody Based RheB Activation Assay Kit Catalog Number: 81201 20 assays NewEast Biosciences 1 FAX: 610-945-2008 Table
More informationIgG TrueBlot Protocol for Mouse, Rabbit or Goatderived Antibodies - For Research Use Only
IgG TrueBlot Protocol for Mouse, Rabbit or Goatderived Antibodies - For Research Use Only Introduction The IgG TrueBlot for mouse, rabbit, or goat-derived antibodies represents unique series of respective
More informationGE Healthcare. GammaBind G Sepharose
GE Healthcare Instructions 71-7057-00 AH Affinity Media GammaBind G Sepharose GammaBind G Sepharose is GammaBind G, Type 2, covalently immobilized to Sepharose 4B by the cyanogen bromide method. GammaBind
More informationProtein G HP SpinTrap Protein G HP MultiTrap Protein A/G SpinTrap Buffer Kit
GE Healthcare Data File 28-9067-90 AB Protein Sample Preparation Protein G HP SpinTrap Protein A/G SpinTrap Buffer Kit Protein G HP SpinTrap and (Fig 1) are designed for the enrichment of proteins of interest,
More informationShort- and Long-Term Immune Responses of CD-1 Outbred Mice to the Scrub Typhus DNA Vaccine Candidate: p47kp
Short- and Long-Term Immune Responses of CD-1 Outbred Mice to the Scrub Typhus DNA Vaccine Candidate: p47kp GUANG XU, a SUCHISMITA CHATTOPADHYAY, a JU JIANG, a TEIK-CHYE CHAN, a CHIEN-CHUNG CHAO, a WEI-MEI
More informationGα i Activation Assay Kit
A helping hand for your research Product Manual Configuration-specific Monoclonal Antibody Based Gα i Activation Assay Kit Catalog Number 80301 20 assays NewEast Biosciences, Inc 1 Table of Content Product
More informationRab5 Activation Assay Kit
A helping hand for your research Product Manual Configuration-specific Monoclonal Antibody Based Rab5 Activation Assay Kit Catalog Number: 83701 20 assays 24 Whitewoods Lane 1 Table of Content Product
More information